Brainsway(US:BWAY) Globenewswire·2026-02-23 13:00Core Viewpoint - BrainsWay Ltd. is a leader in noninvasive brain stimulation technologies, focusing on advancing neuroscience through its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform, which has received FDA clearance for multiple mental health disorders [2]. Group 1: Company Overview - BrainsWay is recognized for its advanced neurostimulation treatments aimed at mental health disorders, with a commitment to improving health and transforming lives [2]. - The company has achieved FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction, supported by pivotal clinical studies [2]. - Founded in 2003, BrainsWay operates in the United States and Israel, with ongoing clinical trials for Deep TMS in various psychiatric, neurological, and addiction disorders [2]. Group 2: Upcoming Events - Management from BrainsWay will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on February 26, 2026, in New York [1].